-
公开(公告)号:PT1025100E
公开(公告)日:2002-07-31
申请号:PT98951491
申请日:1998-10-05
Applicant: BASF AG
Inventor: STEINER GERD , TESCHENDORF HANS-JUERGEN , EMLING FRANZ , WICKE KARSTEN , LUBISCH WILFRIED , DULLWEBER UTA , STARCK DOROTHEA , BACH ALFRED , GARCIA-LADONA XAVIER
IPC: A61K31/519 , A61P1/00 , A61P1/14 , A61P3/04 , A61P5/00 , A61P9/12 , A61P15/00 , A61P25/00 , A61P25/22 , A61P25/24 , A61P25/28 , A61P43/00 , C07D471/00 , C07D471/04
Abstract: 3-substituted tetrahydropyridopyrimidinone derivatives of the formula (I) wherein the radicals have the meanings given in the Description, to a method for producing said derivatives and, to their use for producing active ingredients for drugs.
-
公开(公告)号:DE59510244D1
公开(公告)日:2002-07-18
申请号:DE59510244
申请日:1995-07-14
Applicant: BASF AG
Inventor: HELLENDAHL BEATE , LANSKY ANNEGRET , MUNSCHAUER RAINER , BIALOJAN SIEGFRIED , UNGER LILIANE , TESCHENDORF HANS-JUERGEN , WICKE KARSTEN , DRESCHER KARLA
IPC: C07D239/26 , A61K31/505 , A61K31/506 , A61P25/16 , A61P25/24 , A61P25/26 , C07D239/38 , C07D239/46 , C07D239/56 , C07D239/60 , C07D401/00 , C07D401/12
Abstract: The present invention relates to the use of pyrimidine compounds of the following formula:wherein R1, R2, R3, A, B and Ar have the meanings indicated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
-
133.
公开(公告)号:BG63602B1
公开(公告)日:2002-06-28
申请号:BG10312299
申请日:1999-01-27
Applicant: BASF AG
Inventor: STEINER GERD , LUBISCH WILFRIED , BACH ALFRED , EMLING FRANZ , WICKE KARSTEN , TESCHENDORF HANS-JUERGEN , BEHL BERTHOLD , KERRIGAN FRANK , CHEETHAM SHARON
IPC: A61K31/435 , A61K31/519 , A61P25/24 , A61P43/00 , C07D211/00 , C07D239/00 , C07D333/00 , C07D495/14
Abstract: The 3-substituted 3,4,5,6,7.8-hexahydro-pyrido[4', 3': 4,5]-thieno [2,3-d] pyrimidine derivatives can be used as medicamentous forms for diseases where there is redud serotonin concentration and where, within the therapy, the activity of the presnaptic receptors 5-HT1B-, 5-HT1A-, 5-HT1D-, should be blocked without seriously affecting any other receptors. Depression is an example for such morbid state. The compounds have formula in which R1 is hydrogen, C1-C4-alkyl group, acetyl, benzoyl, phenylalkyl-C1-C4-residue where the aromatic residue is optionally substituted with halogen, C1-C4-alkyl, trifluoromethyl, hydroxy-, C1-C4-alkoxy-, amino-, cyano- or nitrogroups or is naphtalene-C1-C4-alkyl residue, phenylalkanon-C2-C4-residue or phenylcarbamoylalkyl-C2-residue where the phenyl group can be substituted by halogen; R2 optionally is mono-, di- or trisubstituted with halogen atoms, C1-C4-alkyl, trifluoromethyl, trifluormethoxy, hydroxy, C1-C4-alkoxy, amino-, monomethylamino-, diethylamino-, cyano- or nitrogroup, phenyl, pyridyl, pyrimidinyl or pyrasinyl reside which can optionally be ringed by one benzene ring which optionally can be mono- or disubstituted with halogen atom, C1-C4-alkyl, hydroxy, trifluormethyl, C1-C4-alkoxy, amino-, cyano- or nitrogroup, and optionally can contain one nitrogen atom or be ringed by 5- or 6-member ring which can contain one to two oxygen atoms, or can be substituted by phenyl-C1-C2-alkyl, or alkoxygroup, respectively, where the phenyl residue can be substituted with halogen, methyl, trifluormethyl or methoxygroup. A is NH or oxygen, B is hydrogen or methyl, C is hydrogen, methyl or hydroxy, X is nitrogen atom, Y is the group CH2, CH2- CH2, CH2-CH2-CH2 or CH2-CH, Z is nitrogen atom, carbon or CH where the bond between Y and Z can be double, n has the value of 2, 3 or 4. The invention also relates to physiologically acceptable salts of the above compounds. 6 claims
-
134.
公开(公告)号:AU748613B2
公开(公告)日:2002-06-06
申请号:AU1149799
申请日:1998-10-05
Applicant: BASF AG
Inventor: LUBISCH WILFRIED , DULLWEBER UTA , STARCK DOROTHEA , STEINER GERD , BACH ALFRED , EMLING FRANZ , GARCIA-LADONA XAVIER , TESCHENDORF HANS-JURGEN , WICKE KARSTEN
IPC: A61K31/428 , A61P25/24 , A61P43/00 , C07D275/06 , C07D417/04 , C07D417/06 , C07D417/12 , C07D417/14 , A61K31/425
Abstract: where the substituents have the meanings indicated in the description, their preparation and use as serotonin antagonists.
-
公开(公告)号:DK1025100T3
公开(公告)日:2002-05-06
申请号:DK98951491
申请日:1998-10-05
Applicant: BASF AG
Inventor: LUBISCH WILFRIED , DULLWEBER UTA , STARCK DOROTHEA , STEINER GERD , BACH ALFRED , EMLING FRANZ , GARCIA-LADONA XAVIER , TESCHENDORF HANS-JUERGEN , WICKE KARSTEN
IPC: A61K31/519 , A61P1/00 , A61P1/14 , A61P3/04 , A61P5/00 , A61P9/12 , A61P15/00 , A61P25/00 , A61P25/22 , A61P25/24 , A61P25/28 , A61P43/00 , C07D471/00 , C07D471/04
Abstract: 3-substituted tetrahydropyridopyrimidinone derivatives of the formula (I) wherein the radicals have the meanings given in the Description, to a method for producing said derivatives and, to their use for producing active ingredients for drugs.
-
136.
公开(公告)号:AU736678B2
公开(公告)日:2001-08-02
申请号:AU4207197
申请日:1997-08-22
Applicant: BASF AG
Inventor: STEINER GERD , LUBISCH WILFRIED , BACH ALFRED , EMLING FRANZ , WICKE KARSTEN , TESCHENDORF HANS-JURGEN , BEHL BERTHOLD , KERRRIGAN FRANK , CHEETHAM SHARON
IPC: A61K31/435 , A61K31/519 , A61P25/24 , A61P43/00 , C07D211/00 , C07D239/00 , C07D333/00 , C07D495/14
Abstract: A 3-substituted 3,4,5,6,7,8-hexahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidine compound of formula IwhereinR1 is hydrogen, C1-C4-alkyl, acetyl or benzoyl, optionally substituted phenyl-C1-C4-alkyl, naphthyl-C1-C3-alkyl, phenyl-C2-C3-alkanone or a phenylcarbamoyl-C2-alkyl,R2 is optionally substituted phenyl, pyridyl, pyrimidyl or pyrazinyl, or an optionally substituted bicyclus wherein one of the two fused rings is a phenyl, a pyridyl, a pyrimidyl or a pyrazinyl ring,A is NH or oxygen,B is hydrogen or methyl,C is hydrogen, methyl or hydroxyl,X is nitrogen,Y is CH2, CH2-C2, CH2-C2-CH2 or CH2-CH,Z is nitrogen, C or CH, and the linkage between Y and Z is a single or a double bond, andn is 2, 3 or 4,or a physiologically tolerated salt thereof, and compositions comprising them and their use as antagonists of 5HT1B and 5HT1A and for the treatment of depression and related disorders.
-
公开(公告)号:NZ502657A
公开(公告)日:2001-06-29
申请号:NZ50265798
申请日:1998-07-23
Applicant: BASF AG
Inventor: TESCHENDORF HANS-JURGEN , GARCIA-LADONA FRANCISCO JAVIER , EMLING FRANZ , WICKE KARSTEN , STEINER GERD , DULLWEBER UTA , STARCK DOROTHEA , BACH ALFRED
IPC: A61K31/435 , A61P25/24 , C07D495/14
Abstract: A 3-substituted 3,4,5,7-tetrahhydropyrrolo[3',4':4,5]-thieno[2,3-d]pyrimidine derivative of the formula I, wherein, R1is a hydrogen atom, a C1-C4 alkyl group, an acetyl group, a phenylalkyl c1-c4 radical where the aromatic ring is unsubstituted or substituted by halogen, C1-C4 alkyl, trifluoromethyl, hydroxyl, C1-C4 alkoxy, amino, cyano or nitro groups, or is a C1-C3 alkyl carboxylate radical, R2 is a phenyl, pyridyl, pyrimidinyl or pyrazinyl group which is unsubstituted or mono or disubstituted by halogen atoms, C1-C4 alkyl, trifluoromethyl, trifluoromethoxy, hydroxyl, C1-C4 alkoxy, amino, monoethylamino, dimethylamino, cyano or nitro groups, and may be fused to a benzene nucleus which may be mono or disubstituted by halogen atoms, C1-C4 alkyl, hydroxyl, trifluoromethyl, C1-C4 alkoxy, amino, cyano or nitro groups and may contain 1 nitrogen atom, or to a 5 or 6 membered ring which may contain 1-2 oxygen atoms, A is NH or an oxygen atom, Y is CH2, CH2-CH2, CH2-CH2-CH2 or CH2-CH, Z is a nitrogen atom, carbon atom or CH, where the linkage between Y and Z may also be a double bond, and n is 2,3 or 4, or a physiologically tolerated salt thereof. These compounds are useful as selective 5HT1B and/or 5HT1A antagonists.
-
公开(公告)号:HRP20000014A2
公开(公告)日:2001-04-30
申请号:HRP20000014
申请日:2000-01-07
Applicant: BASF AG
Inventor: STARCK DOROTHEA , BLANK STEFAN , TREIBER HANS-JOERG , UNGER LILIANE , NEUMANN-SCHULTZ BARBARA , LE-BRIS THEOPHILE-MARIE , TESCHENDORF HANS-JUERGEN , WICKE KARSTEN
IPC: A61K31/33 , A61K31/41 , A61K31/4196 , A61K31/454 , A61K31/506 , A61K31/53 , A61K31/551 , A61P25/00 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P43/00 , C07D249/08 , C07D249/12 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
Abstract: Triazole compounds of the following formula:where Ar1, A, B and Ar2 have the meanings given in the description, possess a high affinity for the dopamine D3 receptor and can therefore be used for treating diseases which respond to dopamine D3 ligands.
-
公开(公告)号:CZ200036A3
公开(公告)日:2001-03-14
申请号:CZ200036
申请日:1998-07-03
Applicant: BASF AG
Inventor: STARCK DOROTHEA , BLANK STEFAN , TREIBER HANS-JOERG , UNGER LILIANE , NEUMANN-SCHULTZ BARBARA , LE BRIS THEOPHILE-MARIE , TESCHENDORF HANS-JUERGEN , WICKE KARSTEN
IPC: A61K31/33 , A61K31/41 , A61K31/4196 , A61K31/454 , A61K31/506 , A61K31/53 , A61K31/551 , A61P25/00 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P43/00 , C07D249/08 , C07D249/12 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
Abstract: Triazole compounds of the following formula:where Ar1, A, B and Ar2 have the meanings given in the description, possess a high affinity for the dopamine D3 receptor and can therefore be used for treating diseases which respond to dopamine D3 ligands.
-
公开(公告)号:NZ502181A
公开(公告)日:2000-10-27
申请号:NZ50218198
申请日:1998-07-03
Applicant: BASF AG
Inventor: STARCK DOROTHEA , BLANK STEFAN , TREIBER HANS-JORG , UNGER LILIANE , NEUMANN-SCHULTZ BARBARA , LE BRIS THEOPHILE-MARIE , TESCHENDORF HANS-JURGEN , WICKE KARSTEN
IPC: A61K31/33 , A61K31/41 , A61K31/4196 , A61K31/454 , A61K31/506 , A61K31/53 , A61K31/551 , A61P25/00 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P43/00 , C07D249/08 , C07D249/12 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
Abstract: Triazole compounds of formula (I) and (VIII), wherein: Ar1 is an optionally substituted aryl or heteroaryl ring that may be fused to a phenyl ring; A is an alkylene optionally interrupted with a group selected from O, S, NR2, CONR2, COO, CO, a double bond and a triple bond; B is a 6 or 7 membered non-aromatic ring containing 1 or 2 nitrogen atoms; and Ar2 is selected from optionally substituted phenyl, pyridyl, pyrimidinyl or triazinyl. The compounds exhibit high dopamine-D3-receptor affinity.
-
-
-
-
-
-
-
-
-